By Elaine Briseño ( January 8, 2024, 4:57 PM EST) -- A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue from a new ovarian cancer drug, according to a suit filed Monday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.